| Name | Title | Contact Details |
|---|
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
Delivering Genomic Tests that Impact Treatment Decisions GenomeDx develops and commercializes genomic tests for prostate and other urologic cancers that have a direct impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs.
Phycotransgenics, LLC is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interpace Biosciences is a company that provides molecular and related first line diagnostic tests for evaluating risk of cancer, as well as specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted...